Seismic Therapeutic Appoints Julie Eastland as Independent Board Director
Seismic Therapeutic, a machine learning immunology company, has appointed Julie Eastland as an Independent Director to its Board. Ms. Eastland brings over 30 years of experience in finance and strategy within clinical stage biotechnology companies. Her expertise spans the drug development process, from discovery to commercialization, particularly in oncology and immunology.
Ms. Eastland most recently served as CEO and Board Director of Harpoon Therapeutics (HARP), which was acquired by Merck & Co in March 2024. She has held various C-level executive roles in both private and public companies, including ReCode Therapeutics, Rainier Therapeutics, and Cascadian Therapeutics. Her experience includes guiding biotechnology companies through significant organizational growth and navigating financial and operational challenges.
Seismic Therapeutic, una compagnia di immunologia basata sull'apprendimento automatico, ha nominato Julie Eastland come Direttore Indipendente nel suo Consiglio. La signora Eastland porta oltre 30 anni di esperienza in finanza e strategia all'interno di aziende biotecnologiche in fase clinica. La sua esperienza copre l'intero processo di sviluppo dei farmaci, dalla scoperta alla commercializzazione, in particolare nel campo dell'oncologia e dell'immunologia.
La signora Eastland ha recentemente ricoperto il ruolo di CEO e Direttore del Consiglio di Harpoon Therapeutics (HARP), acquisita da Merck & Co nel marzo 2024. Ha ricoperto vari ruoli dirigenziali in aziende sia private che pubbliche, tra cui ReCode Therapeutics, Rainier Therapeutics e Cascadian Therapeutics. La sua esperienza include la guida di aziende biotecnologiche attraverso significativi processi di crescita organizzativa e la navigazione di sfide finanziarie e operative.
Seismic Therapeutic, una empresa de inmunología basada en aprendizaje automático, ha nombrado a Julie Eastland como Directora Independiente de su Junta. La Sra. Eastland aporta más de 30 años de experiencia en finanzas y estrategia en empresas biotecnológicas en etapa clínica. Su experiencia abarca todo el proceso de desarrollo de medicamentos, desde el descubrimiento hasta la comercialización, particularmente en oncología e inmunología.
La Sra. Eastland se desempeñó más recientemente como CEO y Directora de la Junta de Harpoon Therapeutics (HARP), que fue adquirida por Merck & Co en marzo de 2024. Ha ocupado varios roles ejecutivos de nivel C en empresas privadas y públicas, incluyendo ReCode Therapeutics, Rainier Therapeutics y Cascadian Therapeutics. Su experiencia incluye guiar a las empresas biotecnológicas a través de un crecimiento organizacional significativo y navegar desafíos financieros y operativos.
Seismic Therapeutic, 기계 학습 면역학 회사,가 Julie Eastland를 이사회 독립 이사로 임명했습니다. Eastland씨는 임상 단계 생명공학 회사에서 30년 이상의 경험을 갖고 있으며, 그녀의 전문 지식은 약물 개발 프로세스 전반, 즉 발견에서 상업화에 이르기까지, 특히 암 및 면역학 분야에 걸쳐 있습니다.
Eastland씨는 최근에 Harpoon Therapeutics(HARP)의 CEO 및 이사회 이사로 재직했으며, 이 회사는 2024년 3월 Merck & Co에 인수되었습니다. 그녀는 ReCode Therapeutics, Rainier Therapeutics 및 Cascadian Therapeutics를 포함한 여러 민간 및 공공 기업에서 다양한 C급 경영직을 역임했습니다. 그녀의 경험은 생명공학 기업이 중요한 조직 성장을 이루고 재정 및 운영 문제를 극복하는 데 도움을 주는 것을 포함합니다.
Seismic Therapeutic, une entreprise d'immunologie spécialisée dans l'apprentissage automatique, a nommé Julie Eastland en tant que Directrice Indépendante de son Conseil d'administration. Mme Eastland apporte plus de 30 ans d'expérience en finance et stratégie au sein d'entreprises biopharmaceutiques en phase clinique. Son expertise couvre l'ensemble du processus de développement des médicaments, de la découverte à la commercialisation, en particulier dans le domaine de l'
Mme Eastland a récemment été PDG et Directrice du Conseil de Harpoon Therapeutics (HARP), qui a été acquise par Merck & Co en mars 2024. Elle a occupé divers postes de direction au sein d'entreprises privées et publiques, notamment chez ReCode Therapeutics, Rainier Therapeutics et Cascadian Therapeutics. Son expérience inclut l'accompagnement des entreprises biopharmaceutiques à travers une croissance organisationnelle significative et la gestion des défis financiers et opérationnels.
Seismic Therapeutic, ein Unternehmen für Immunologie, das auf maschinellem Lernen basiert, hat Julie Eastland als unabhängige Direktorin in seinen Vorstand berufen. Frau Eastland bringt über 30 Jahre Erfahrung in Finanzen und Strategie innerhalb von biotechnologischen Unternehmen in der klinischen Phase mit. Ihre Expertise umfasst den gesamten Prozess der Arzneimittelentwicklung, von der Entdeckung bis zur Vermarktung, insbesondere in der Onkologie und Immunologie.
Frau Eastland war zuletzt als CEO und Vorstandsdirektorin von Harpoon Therapeutics (HARP) tätig, das im März 2024 von Merck & Co übernommen wurde. Sie hat verschiedene Top-Management-Positionen in privaten und öffentlichen Unternehmen innegehabt, darunter ReCode Therapeutics, Rainier Therapeutics und Cascadian Therapeutics. Ihre Erfahrung umfasst die Begleitung biotechnologischer Unternehmen durch bedeutendes organisatorisches Wachstum und die Bewältigung finanzieller und operativer Herausforderungen.
- Appointment of Julie Eastland brings 30+ years of biotech industry experience to the board
- Eastland's expertise spans finance, strategy, and drug development from discovery to commercialization
- Addition of experienced leader may help guide Seismic through organizational growth and pipeline advancement
- None.
“It is with much excitement that we welcome Julie to our Board of Directors. As a proven independent Director and executive with decades of experience in the biopharmaceutical industry, Julie brings deep knowledge across the company growth and drug development continuum, from discovery through commercialization,” said Jo Viney, PhD, Co-founder, President and CEO of Seismic Therapeutic. “Julie’s wide range of leadership roles, experience with platform and asset-focused companies, and successful track record guiding biotechnology companies through significant organizational growth, and background spanning strategy, financial and operational perspectives will serve us well as we continue to mature our business and advance our first pipeline candidates into the clinic.”
“It is a privilege to join Seismic’s Board as the company continues to make a major shift in how immunology therapies are discovered and developed, enabled by machine learning,” said Julie Eastland. “I look forward to working with the accomplished team at Seismic as we build and advance a clinical pipeline of innovative enzyme and antibody drug programs to modulate the immune system in new and better ways. I believe Seismic’s approach has the potential to result in powerful, novel treatments for patients suffering from autoimmune diseases of high unmet need.”
Ms. Eastland most recently served as Chief Executive Officer and Board Director of Harpoon Therapeutics, formerly a publicly traded company (Nasdaq: HARP) focused on T-cell engager cancer immunotherapies, from November 2021 through its acquisition by Merck & Co in March of 2024. Prior to November 2021, she was a Harpoon Board Director and Chair of the Audit Committee from October 2018. Ms. Eastland has served in a variety of C-level executive roles for both private and public companies, including Chief Operating Officer/Chief Financial Officer for ReCode Therapeutics, a private company developing genetic medicines; Chief Financial Officer/Chief Business Officer for Rainier Therapeutics, a private company focused on FGFR3 in bladder cancer; Chief Financial Officer/Chief Business Officer for Cascadian Therapeutics, a public company (CASC) focused on Tukysa (tucantinib) in HER2+ breast cancer, through its acquisition by Seagen in 2018. Prior to Cascadian, Ms. Eastland served in a number of financial and strategic roles for VLST Corporation, focused on autoimmune and inflammation biology, Dendreon, an oncology cell therapy company marketing Provenge for prostate cancer, and Amgen.
Ms. Eastland currently serves as a Board member and audit chair at Dynavax Technologies (DVAX), board and audit committee member at Lantheus Holdings Inc (LNTH) and board member at Veana Therapeutics (private). Previously, she was a Board Director and Chair of the Audit Committee for Graybug Vision and Harpoon Therapeutics. She received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923345608/en/
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com
Source: Seismic Therapeutic, Inc.
FAQ
Who is Julie Eastland and what is her new role at Seismic Therapeutic?
What was Julie Eastland's most recent position before joining Seismic Therapeutic's board?
How might Julie Eastland's experience benefit Seismic Therapeutic?
What other board positions does Julie Eastland currently hold?
